Andy Hill's publications

1. Brazier MW, Lewis V, Ciccotosto GD, Klug GM, Lawson VA, Cappai R, Ironside JW, Masters CL, Hill AF, White AR, Collins SJ. 2005. Correlative studies support lipid peroxidation is linked to PrP^scrapie propagation as an early primary pathogenic event in prion disease. Brain Research Bulletin (in press).
   
2. Collins SJ, Lewis VL, Brazier MW, Hill AF, Lawson VA, Klug GM, Masters CL. 2005. Extended period of asymptomatic prion (Creutzfeldt-Jakob disease) infection after low dose inoculation: assessment of detection methods and implications for infection control. Neurobiology of Disease. (in press).


3. Lewis V, Hill AF, Klug G, Boyd A, Masters CL, Collins SJ. 2005. Analysis of Australian sporadic CJD supports non-environmental determinants of molecular-clinical profiles. Neurology, 65(1):113-8.


4. Cappai R, Leck S-L, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, Curtain CC, Ali FE, Cherny RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ, Hill AF. 2005. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB Journal, 19(10):1377-9.


5. Lawson VA, Collins SJ, Masters CL, Hill AF, 2005. Prion protein glycosylation. Journal of Neurochemistry, 93;793-801.


6. Vella L, Hill AF, Cappai R. 2005. Neurotoxicity of the prion peptide PrP106-126: cellular and biophysical correlates. In Neurodegeneration and Prion Disease, edited by David Brown.


7. Turner BJ, Atkin JD, Farg MA, Zang da W, Rembach A, Lopes EC, Patch JD, Hill AF, Cheema SS. 2005. Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. Journal of Neuroscience, 25(1):108-17.


8. Wadsworth J, Asante EA, Debruslais M, Linehan M, Joiner S, Gowland I, Welch J, Stone L, Lloyd SE, Hill AF, Brandner S, Collinge J. 2004. Human prion protein V129 prevents expression of variant CJD phenotype. Science, 306(5702):1793-6.


9. Hill AF. 2004. Identification of a new prion strain in cattle – is there more than one form of BSE? Australian Veterinary Journal, 82(5):17-20.


10. Hill AF, Collinge J. 2004. Prion strains and species barriers. Contributions to Microbiology, 11:33-49.


11. Hill AF, Collinge J. 2003. Subclinical prion infection. Trends in Microbiology, 11(12):578-84.


12. Hill, AF, Asante E, Collinge J. 2003. Bioassays for prions. In Prions and Mad Cow Disease, Brian Nunnally and Ira Krull, eds. Dekker Press, New York


13. Nunan J, Williamson NA, Hill AF, Sernee MF, Masters CL, Small DH. 2003. Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein. Neuroscience Research, 74(3):378-85.


14. Wadsworth JD, Hill AF, Beck JA, Collinge J. 2003. Molecular and clinical classification of human prion disease. British Medical Bulletin, 66:241-54.


15. Hill AF, Collinge J. 2003. Subclinical prion infection in humans and animals. British Medical Bulletin, 66:161-70.


16. Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, Budka H, Ironside JW, Collinge J. 2003. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain, 126:1333-46.


17. Lewis V, Collins S, Hill AF, Boyd A, McLean CA, Smith M, Masters CL. 2003. Novel prion protein insert mutation associated with prolonged neurodegenerative illness. Neurology, 60(10):1620-4.


18. Hill AF. 2003. Possible link between bovine spongiform encephalopathy and sporadic Creutzfeldt-Jakob disease. Australian Veterinary Journal, 81:275-77.


19. Asante EA, Linehan JM, Desbruslais M, Joiner S, Gowland I, Wood AL, Welch J, Hill AF, Lloyd SE, Wadsworth JD, Collinge J. 2002. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO Journal, 21(23):6358-66.


20. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. 2002. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Annals of Neurology, 52(4):503-6.


21. Collins S, Boyd A, Fletcher A, Kaldor J, Hill AF, Farish S, McLean C, Ansari Z, Smith M, Masters CL. 2002. Creutzfeldt-Jakob disease cluster in an Australian rural city. Annals of Neurology, 52(1):115-8.


22. Hill AF, Collinge J. 2002. Species-barrier-independent prion replication in apparently resistant species. APMIS, 110(1):44-53.


23. Hill AF, Collinge J. 2001. Strain variations and species barriers. Microbiology, 7:48-57


24. Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, Collinge J. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. The Lancet, 358(9277):171-80.


25. White AR, Guirguis R, Brazier MW, Jobling MF, Hill AF, Beyreuther K, Barrow CJ, Masters CL, Collins SJ, Cappai R. 2001. Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons. Neurobiol Disease, 8(2):299-316.


26. Hill AF, Joiner S, Linehan J, Desbruslais M, Lantos PL, Collinge J. 2000. Species-barrier-independent prionreplication in apparently resistant species. Proceedings of the National Academy of Science USA, 97(18):10248-53.


27. Wadsworth JD, Hill AF, Joiner S, Jackson GS, Clarke AR, Collinge J. 1999. Strain-specific prion-protein conformation determined by metal ions. Nature Cell Biology, 1(1):55-9.


28. Wadsworth JD, Jackson GS, Hill AF, Collinge J. 1999. Molecular biology of prion propagation. Current Opinion in Genetic Development, 9(3):338-45.


29. Jackson GS, Hill AF, Joseph C, Hosszu L, Power A, Waltho JP, Clarke AR, Collinge J. 1999. Multiple folding pathways for heterologously expressed human prion protein. Biochimica Biophysica Acta, 1431(1):1-13.


30. Jackson GS, Hosszu LL, Power A, Hill AF, Kenney J, Saibil H, Craven CJ, Waltho JP, Clarke AR, Collinge J. 1999. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science, 283(5409):1935-7.


31. Almer G, Hainfellner JA, Brucke T, Jellinger K, Kleinert R, Bayer G, Windl O, Kretzschmar HA, Hill A, Sidle K, Collinge J, Budka H. 1999. Fatal familial insomnia: a new Austrian family. Brain, 122:5-16.


32. Hill AF, Antoniou M, Collinge J. 1999. Protease-resistant prion protein produced in vitro lacks detectable infectivity. Journal of General Virology, 80:11-4.


33. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, Frosh A, Tolley N, Bell JE, Spencer M, King A, Al-Sarraj S, Ironside JW, Lantos PL, Collinge J. 1999. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet, 353(9148):183-9.


34. Hill AF Sidle KC, Joiner S, Keyes P, Martin TC, Dawson M, Collinge J. 1998. Molecular screening of sheep for bovine spongiform encephalopathy. Neuroscience Letters, 255(3):159-62.


35. Piccardo P, Langeveld JP, Hill AF, Dlouhy SR, Young K, Giaccone G, Rossi G, Bugiani M, Bugiani O, Meloen RH, Collinge J, Tagliavini F, Ghetti B. 1998. An antibody raised against a conserved sequence of the prion protein recognizes pathological isoforms in human and animal prion diseases, including Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. American Journal of Pathology, 152(6):1415-20.


36. Jackson G, Hill AF, Joseph C, Clarke A, Collinge J. 1998. Structural properties of recombinant human prion protein. In Prions and Brain Diseases in Animals and Humans, edited by Morrison, Plenum Press, New York. pp197-202.


37. Collinge J, Beck J, Campbell TA, Desbruslais M, Gowland I, Hill AF, Mahal S, Meads J, Sidle KCL, Jefferys JGR. 1998. Molecular, genetic and transgenetic studies of human prion disease. In Prions and Brain Diseases in Animals and Humans, edited by Morrison, Plenum Press, New York. pp303-305.


38. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge J, Doey LJ, Lantos P. 1997. The same prion strain causes vCJD and BSE. Nature, 389(6650):448-50, 526.


39. Collinge J, Hill AF, Sidle KCL, Ironside J. 1997. Biochemical typing of scrapie strains. Nature, 386:564.


40. Hill AF, Will RG, Ironside J, Collinge J. 1997. Type of prion protein in farmers with Creutzfeldt-Jakob disease. The Lancet, 350(9072):188.


41. Collinge J, Hill AF, Ironside J, Zeidler M. 1997. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. The Lancet, 349:1322-3.


42. Hill AF, Zeidler M, Ironside J, Collinge J. 1997. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. The Lancet, 349(9045):99-100


43. Collinge J, Hill AF, Sidle KCL, Ironside J. 1997. Typing prion isoforms. Nature, 86:233-4


44. Deslys JP, Lasmezas CI, Streichenberger N, Hill A, Collinge J, Dormont D, Kopp N. 1997. New variant Creutzfeldt-Jakob disease in France. The Lancet, 349(9044):30-1.


45. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. 1997. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature, 383(6602):685-90.


46. Collinge J, Palmer MS, Sidle KC, Hill AF, Gowland I, Meads J, Asante E, Bradley R, Doey LJ, Lantos PL. 1995. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature, 378(6559):779-83.


47. Whittington MA, Sidle KC, Gowland I, Meads J, Hill AF, Palmer MS, Jefferys JG, Collinge J. 1995. Rescue of neurophysiological phenotype seen in PrP null mice by transgene encoding human prion protein. Nature Genetics, 9(2):197-201.


48. Collinge J, Palmer MS, Gowland I, Sidle KCL, Hill AF, Meads J. 1995. Transmission of human prion disease to transgenic mice expressing human prion protein. Quarterly Journal of Medicine, 88:839-40.


49. Palmer MS, Mahal SP, Campbell TA, Hill AF, Sidle KC, Laplanche JL, Collinge J. Deletions in the prion protein gene are not associated with CJD. Human Molecular Genetics, 2(5):541-4.